Synthesis of phosphoramide mustard analogues of daunomycin and carminomycin. 1998

A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
Research Group for Antibiotics of the Hungarian Academy of Sciences, L. Kossuth University, Debrecen, Hungary.

New phosphoramide mustards (6-8) have been prepared from the antibiotics 2 and 3, and from 5. The mixture of cyclophosphamides could be separated by preparative layer and column chromatography. The assignments of configuration to the isomeric phosphoramidates was based on the magnetic anisotropy of the P = O bond. The synthesized compounds 6a,b-8a,b (mixture of isomers) were tested for inhibitory activity on the [3H]-thymidine incorporation into the DNA of tumor cells, using ovarian carcinoma cell line.

UI MeSH Term Description Entries
D010752 Phosphoramide Mustards A group of nitrogen mustard compounds which are substituted with a phosphoramide group or its derivatives. They are usually cytotoxic and used as antineoplastic agents. Mustards, Phosphoramide
D002360 Carubicin A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata. Carminomycin,Karminomycin,Carminomicin,Carminomycin I,Carminomycin II,Carminomycin III,Carubicin Hydrochloride,Demethyldaunomycin,Demethyldaunorubicin,Karminomicin,NSC-180,024,NSC-180024,Rubeomycin A,Rubeomycin A1,Hydrochloride, Carubicin,NSC 180,024,NSC 180024,NSC180,024,NSC180024
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating

Related Publications

A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
August 2001, Acta pharmaceutica Hungarica,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
November 1980, Journal of medicinal chemistry,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
March 1976, Cancer research,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
June 1995, Journal of medicinal chemistry,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
January 2017, Reproductive toxicology (Elmsford, N.Y.),
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
November 1993, Journal of medicinal chemistry,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
January 1982, The Journal of antibiotics,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
December 2017, ACS medicinal chemistry letters,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
November 1980, Cancer research,
A Csorvási, and K E Kövér, and M M Menyhárt, and F Sztaricskai, and Y V Dobrynin, and T G Nikolaeva
September 1981, The Journal of antibiotics,
Copied contents to your clipboard!